Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.
Editas Medicine has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Editas Medicine's investors include Khosla Ventures, Omega Funds, Fidelity, Third Rock Ventures, Google Ventures.
Editas Medicine is headquartered in Cambridge, United States.
Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.
Editas Medicine is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Editas Medicine — Funding & Investors." VCBacked, May 26, 2026, https://www.vcbacked.co/company/editas-medicine. Accessed August 14, 2026.
VCBacked. (2026). Editas Medicine — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/editas-medicine
{{cite web |title=Editas Medicine — Funding & Investors |url=https://www.vcbacked.co/company/editas-medicine |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated